Brief: Advaxis Announces FDA Clearance Of New IND For ADXS-504 For Treatment Of Prostate Cancer
24/09/2020 13:55
Sept 24 (Reuters) - Advaxis Inc ADXS.O :
* ADVAXIS ANNOUNCES FDA CLEARANCE OF NEW IND FOR ADXS-504
FOR
TREATMENT OF PROSTATE CANCER
* ADVAXIS INC - INITIATION OF INVESTIGATOR SPONSORED PHASE 1
STUDY
OF ADXS-504 IN PROSTATE CANCER ON-TRACK FOR Q4 2020
Source text for Eikon: ID:nGNX5NzxQD
Further company coverage: ADXS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ayala Pharmaceuticals
See all newsBrief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals
Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors